Table 1 Correlation of clinical variables and S. aureus clonal complexes
Variable | Overall n = 49 n (%a), median (IQR) | At least one isolate ST93 n = 24 n (%), median (IQR) | At least one isolate CC121 n = 15 n (%), median (IQR) | Other clonal complexes n = 10 n (%), median (IQR) |
|---|---|---|---|---|
Demographics | ||||
Ethnicity: Indigenous | 44 (89.8) | 22 (91.7) | 14 (93.3) | 8 (80.0) |
Gender: Female | 29 (59.2) | 12 (50.0) | 9 (60.0) | 8 (80.0) |
Age (years) | 30.0 [10.0, 46.0] | 28.5 [11.2, 47.0] | 34.0 [24.5, 45.5] | 20.5 [4.5, 42.2] |
Residence | ||||
Town camp | 12 (24.5) | 6 (25.0) | 4 (26.7) | 2 (20.0) |
Remote community | 24 (49.0) | 12 (50.0) | 6 (40.0) | 6 (60.0) |
Prison | 1 (2.0) | 1 (6.7) | ||
Visitor | 2 (4.1) | 1 (4.2) | 1 (10.0) | |
House in Alice Springs | 10 (20.4) | 5 (20.8) | 4 (26.7) | 1 (10.0) |
Co-morbidities | ||||
Diabetes mellitus | 22 (44.9) | 12 (50.0) | 6 (40.0) | 4 (40.0) |
Chronic kidney disease | 12 (24.5) | 6 (25.0) | 3 (20.0) | 3 (30.0) |
Haemodialysis | 2 (4.1) | 2 (8.3) | 0 (0.0) | 0 (0.0) |
Excess alcohol use | 6 (12.2) | 3 (12.5) | 2 (13.3) | 1 (10.0) |
Obesity (BMI ≥ 30) | 13 (26.5) | 3 (12.5) | 7 (46.7) | 3 (30.0) |
Cardiac failure | 6 (12.2) | 2 (8.3) | 3 (20.0) | 1 (10.0) |
Ischaemic heart disease | 4 (8.2) | 2 (8.3) | 1 (6.7) | 1 (10.0) |
Scabies | 12 (24.5) | 5 (20.8) | 4 (26.7) | 3 (30.0) |
Asthma | 5 (10.2) | 1 (4.2) | 1 (6.7) | 3 (30.0) |
Healthcare exposure | ||||
Admission in previous 6 months | 18 (38.3) | 9 (39.1) | 5 (33.3) | 4 (44.4) |
Previous CA- MRSA | 18 (38.3) | 10 (43.5) | 3 (20.0) | 5 (55.6) |
Clinical presentation | ||||
Size (cm) | 4.0 [3.0, 5.0] | 4.0 [2.5, 5.0] | 4.0 [3.0, 6.0] | 5.5 [3.5, 9.0] |
Duration (days) | 5.0 [2.0, 7.0] | 5.5 [3.2, 7.0] | 4.0 [2.0, 6.5] | 3.0 [2.0, 7.0] |
Site of infection | ||||
Head & neck | 8 (16.3) | 5 (20.8) | 3 (20.0) | |
Upper limb | 9 (18.4) | 7 (29.2) | 1 (6.7) | 1 (10.0) |
Torso | 6 (12.2) | 3 (12.5) | 13.3 (2) | |
Buttock/groin/thigh | 12 (24.5) | 6 (25.0) | 2 (13.3) | 1 (10.0) |
Lower leg | 11 (22.4) | 2 (8.3) | 26.7 (4) | 3 (30.0) |
Multiple | 3 (6.1) | 1 (4.2) | 13.3 (2) | 5 (50.0) |
Treatment | ||||
Time to surgery (days) | 1.0 [1.0, 1.0] | 1.0 [1.0, 1.0] | 1.0 [1.0, 1.0] | 1.0 [1.0, 1.0] |
Antimicrobials prior surgery | ||||
Inactive | 18 (36.7) | 13 (54.2) | 5 (50.0) | |
Active | 30 (61.2) | 10 (41.7) | 15 (100.0) | 5 (50.0) |
Planned oral antibiotic duration (days) | 7.0 [2.0, 7.0] | 6.5 [3.2, 7.0] | 5.0 [0.0, 7.0] | 7.0 [5.5, 7.0] |
Clinical outcomes | ||||
Length of stay (days) | 3.0 [2.0, 7.0] | 3.0 [3.0, 6.0] | 2.0 [2.0, 6.5] | 3.0 [2.2, 7.0] |
Progression to deep structures | 5 (11.9) | 3 (15.0) | 0 (0.0) | 2 (25.0) |
Secondary infection | 1 (2.5) | 0 (0.0) | 1 (7.7) | 0 (0.0) |
Return to theatre | 6 (12.5) | 6 (26.1) | 0 (0.0) | 0 (0.0) |
Readmission within 30 days | 4 (8.3) | 2 (8.7) | 2 (13.3) | 0 (0.0) |
Unscheduled medical review | 8 (21.1) | 4 (23.5) | 2 (15.4) | 2 (25.0) |
Repeat antibiotics required | 10 (26.3) | 3 (17.6) | 6 (46.2) | 1 (12.5) |
Antimicrobial susceptibility | ||||
Methicillin resistance | 28 (57.1) | 23 (95.8) | 0 (0.0) | 5 (50.0) |
Clindamycin resistance | 3 (12.5) | 9 (60.0) | ||
Trimethoprim/sulfamethoxazole resistance | 0 (0.0) | 0 (0.0) | ||